Cryo Cell International (CCEL) Current Deferred Revenue (2010 - 2026)

Cryo Cell International has disclosed Current Deferred Revenue across 17 years of filings, most recently posting $9.4 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 83.63% year-over-year to $9.4 million; the TTM figure through Feb 2026 stood at $9.4 million (down 83.63% YoY), while the FY2025 annual figure was $9.7 million, down 82.73% from the prior year.
• Current Deferred Revenue fell to $9.4 million in Q1 2026, from $9.7 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for CCEL reached as high as $57.2 million in Q1 2025 and fell as low as $9.4 million in Q1 2026.
• The 5-year median for Current Deferred Revenue is $46.5 million (2023), against an average of $40.1 million.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue gained 12.84% — and 2026, when it sank 83.63%.
• A 5-year view of Current Deferred Revenue shows it stood at $45.6 million in 2022, then climbed by 11.64% to $50.9 million in 2023, then rose by 10.72% to $56.3 million in 2024, then plunged by 82.73% to $9.7 million in 2025, then fell by 3.83% to $9.4 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $9.4 million, $9.7 million, and $9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.